BioSpace News Archive

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today shared an update on its response to the COVID-19 pandemic and a current assessment of the impact on AVROBIO’s operations.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the year ended December 31, 2019 and provided a corporate strategic update.

Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, provides a business update related to the COVID-19 situation.

IMV Inc. (the “Company” or “IMV”) (TSX:IMV; NASDAQ:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and full year ended December 31, 2019.

George Hart, M.D. and Terry Ketchersid, M.D. to Lead Physician-driven Renal Population Health Management Company

Junshi Biosciences announced the approval of its proposed A-share listing by the Listing Committee for the Shanghai Stock Exchange STAR Market.

Viva Biotech Holdings announced its annual results for the twelve months ended 31 December 2019.

The following are updates to trade shows, conferences and events impacted by the novel coronavirus (COVID-19) pandemic.